Accueil   Diary - News   All news Poxel Announces PXL770 Advances into a Phase 1b Multiple Ascending Dose Trial

Poxel Announces PXL770 Advances into a Phase 1b Multiple Ascending Dose Trial

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes, announced today that it has initiated a Phase 1b multiple ascending dose (MAD) trial for PXL770 and subjects have been dosed.

 

The MAD trial will include up to 76 subjects and evaluate the safety, tolerability and pharmacokinetics of PXL770 in at least four dose groups. Completion of the MAD trial is anticipated in early 2018.

 

Read the press release